CN1794975A - 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂 - Google Patents

使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂 Download PDF

Info

Publication number
CN1794975A
CN1794975A CNA2004800116680A CN200480011668A CN1794975A CN 1794975 A CN1794975 A CN 1794975A CN A2004800116680 A CNA2004800116680 A CN A2004800116680A CN 200480011668 A CN200480011668 A CN 200480011668A CN 1794975 A CN1794975 A CN 1794975A
Authority
CN
China
Prior art keywords
compositions
surfactant
acid
antimicrobial
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800116680A
Other languages
English (en)
Chinese (zh)
Inventor
巴雷特·E·拉比诺
兰迪·怀特
孙宗逊
王重德
詹姆士·E·基普
马克·J·多蒂
克里斯廷·L·里贝克
帕夫洛斯·帕帕佐普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of CN1794975A publication Critical patent/CN1794975A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CNA2004800116680A 2003-04-29 2004-04-29 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂 Pending CN1794975A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46635403P 2003-04-29 2003-04-29
US60/466,354 2003-04-29

Publications (1)

Publication Number Publication Date
CN1794975A true CN1794975A (zh) 2006-06-28

Family

ID=33418369

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800116680A Pending CN1794975A (zh) 2003-04-29 2004-04-29 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂

Country Status (11)

Country Link
EP (1) EP1617818A1 (https=)
JP (1) JP2006525345A (https=)
KR (1) KR20060015553A (https=)
CN (1) CN1794975A (https=)
AU (1) AU2004234003A1 (https=)
BR (1) BRPI0409929A (https=)
CA (1) CA2523151A1 (https=)
MX (1) MXPA05011607A (https=)
NO (1) NO20055616L (https=)
WO (1) WO2004096180A1 (https=)
ZA (1) ZA200508467B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102085176A (zh) * 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
CN102106832A (zh) * 2011-02-12 2011-06-29 华中师范大学 酮康唑纳米混悬剂冻干粉及其制备方法
JP2022009026A (ja) * 2015-07-07 2022-01-14 ライフラフト バイオサイエンシーズ，インコーポレイテッド 低ナトリウムポロキサマー１８８製剤および使用方法
CN114344245A (zh) * 2020-06-12 2022-04-15 浙江普利药业有限公司 伏立康唑外用制剂及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100858508B1 (ko) 2005-12-23 2008-09-12 주식회사 삼양사 아졸계 항진균제를 포함하는 조성물 및 그의 제조방법
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
ES2476240T3 (es) * 2010-12-30 2018-03-06 Aktsionernoye Obshchestvo "Nauchnyi Tsentr Protivoinfektsionnyh Preparatov" Agente antibacteriano para el tratamiento de enfermedades infecciosas de origen bacteriano
IT202000030443A1 (it) * 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
WO2025023975A1 (en) * 2023-07-27 2025-01-30 Bard Peripheral Vascular, Inc. Methods for the preparation of phospholipid bilayer carriers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100635456B1 (ko) * 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
NZ526608A (en) * 2000-12-22 2006-06-30 Baxter Int Method for preparing submicron particle suspensions
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102085176A (zh) * 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
CN102106832A (zh) * 2011-02-12 2011-06-29 华中师范大学 酮康唑纳米混悬剂冻干粉及其制备方法
JP2022009026A (ja) * 2015-07-07 2022-01-14 ライフラフト バイオサイエンシーズ，インコーポレイテッド 低ナトリウムポロキサマー１８８製剤および使用方法
JP7298818B2 (ja) 2015-07-07 2023-06-27 ライフラフト バイオサイエンシーズ，インコーポレイテッド 低ナトリウムポロキサマー１８８製剤および使用方法
CN114344245A (zh) * 2020-06-12 2022-04-15 浙江普利药业有限公司 伏立康唑外用制剂及其制备方法

Also Published As

Publication number Publication date
NO20055616L (no) 2006-01-25
KR20060015553A (ko) 2006-02-17
NO20055616D0 (no) 2005-11-28
AU2004234003A1 (en) 2004-11-11
CA2523151A1 (en) 2004-11-11
JP2006525345A (ja) 2006-11-09
ZA200508467B (en) 2006-09-27
MXPA05011607A (es) 2005-12-15
BRPI0409929A (pt) 2006-04-25
EP1617818A1 (en) 2006-01-25
WO2004096180A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
CN1703201A (zh) 用于医药用途的固体粒子抗真菌组合物
US8263131B2 (en) Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug
CN1791386A (zh) 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
CN106794251B (zh) 阿立哌唑前体药物组合物
JP2019516789A (ja) フルベストラント配合物およびその使用方法
CN1913871A (zh) 用于提高中枢神经系统投递的抗－逆转录病毒药剂的纳米悬浮液
CN1794975A (zh) 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂
Elsebay et al. Nanosuspension: a formulation technology for tackling the poor aqueous solubility and bioavailability of poorly soluble drugs
CN1750811A (zh) 在冷冻水基质中包括颗粒的稳定组合物
HK1088536A (en) Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
HK40049829A (en) Aripiprazole prodrug compositions
CN101035511A (zh) 形成非层状分散体的组合物
HK40049829B (zh) 阿立哌唑前体药物组合物
HK1103974A (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
HK1087919A (en) Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
HK1235285B (en) Aripiprazole prodrug compositions
HK1235285A1 (en) Aripiprazole prodrug compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1088536

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1088536

Country of ref document: HK